Skip to content

Perfusion and Hypoxia Evaluation in Tumors Using 18F-FDG PET/CT

Tumor Perfusion and Hypoxia Evaluation and Comparation in 18F-FDG PET/CT

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03373994
Enrollment
40
Registered
2017-12-14
Start date
2016-11-01
Completion date
2020-12-31
Last updated
2020-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perfusion and Hypoxia

Keywords

FDG, perfusion, hypoxia, tumor, PET

Brief summary

Investigators want to use 18F-FDG PET/CT imaging to reflect tumor perfusion and hypoxia.

Detailed description

Perfusion and hypoxia were independent prognositic parameters for tumor patients. Developing a method that can evaluate tumor perfusion and hypoxia noninvasively and conveniently was in urgent need. 18F-FDG PET/CT imaging could reflect tumor hypoxia in 60min balanced imaging was proved and accepted. Moreover, FDG could diffuse out of the vasculature and through cell membranes passively and rapidly due to its lipophilicity, its regional uptake at initial times is expected to reflect tumor perfusion. So, investigators want to use 18F-FDG PET/CT imaging to evaluate tumor perfusion and hypoxia simutaniously,in order to guide the clinical diagnosis and treatment.

Interventions

DIAGNOSTIC_TEST18F-FDG PET/CT initial-time imaging

18F-FDG intravenous bolus injection after a fasting perid of more than 6 hours, simultaneously,PET/CT imaging using one bed lasting 5 minutes was underwent.

DIAGNOSTIC_TEST18F-FDG PET/CT balanced-time imaging

18F-FDG intravenous injection after a fasting perid of more than 6 hours. After 60 minutes, PET/CT imaging using 6-7 bed positions each lasting 2 minutes was underwent.

Sponsors

Harbin Medical University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 1.solid tumor proved by pathology(d\>3.0cm); * 2.age\>18-year-old; * 3\. Karnofsky performance status \>70; * 4.sign the informed consent.

Exclusion criteria

* 1.There are obvious metal implants near the tumor; * 2.Can not lie still for 15 minutes. * 3.Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Correlation of the distribution of FDG between initial-time and balanced-time PET/CT2018.1Initial-time and balanced-time PET/CT imaging were registrated using PET/CT Compare software in GE AW4.6 workstation. FDG distribution was evaluated in each imaging and the correlation was evaluated.

Secondary

MeasureTime frameDescription
SUVs in initial-time and balanced-time PET/CT2018.1the SUVmax and SUVmean was calculated in well-perfused area and hypoxia area in tumors using PET/CT Render software in GE AW4.6 workstation.

Countries

China

Contacts

Primary ContactYingying Sun, Dr
505679386@qq.com13936447513

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026